The Effect of Beta-glucan in Non-Small Cell Lung Cancer
Beta-glucan's Immuno-modulatory Effect on Non-Small Cell Lung Cancer
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
In plain language
This study tests how beta-glucan affects the immune system, which helps the body fight illness. It is for people with known or suspected non-small cell lung cancer. One part is for people whose cancer can be removed by surgery.
The purpose of this study is to determine how beta-glucan affects the immune system in subjects with non-small cell lung cancer.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Who can join
- Aim 2: Have known or suspected non-small cell lung cancer.
- Aim 2: Have never had cancer treatment, or have had none in the past 6 months.
- Aim 2: Have an ECOG daily activity score of 0 to 3, ranging from fully active to needing help with daily care.
- Aim 3: A chest surgeon must decide that your lung cancer can be removed and that you can have surgery.
- Aim 3: Have never had cancer treatment.
- Aim 3: Have an ECOG daily activity score of 0 to 2, meaning you can care for yourself and are up more than half the day.
- Both parts: Be able to swallow pills and have at least 1,500 neutrophils (infection-fighting white blood cells) per microliter of blood.
- Both parts: Be able to understand and willing to sign a written form agreeing to join.
Who can't join
- Both parts: Have had an allergic reaction to beta-glucan.
- Both parts: Take steroids continuously or receive other ongoing treatment that weakens the immune system.
- Both parts: Have an uncontrolled illness, such as an active infection, heart failure with symptoms, unstable chest pain, or an abnormal heartbeat.
- Both parts: Have a mental health condition or life situation that would make it hard to follow study rules.
Simplified for readability. The official criteria below are what the study team uses.
Official eligibility criteria
AIM 2: Inclusion Criteria: * suspected or definitive diagnosis of non-small cell lung cancer (NSCLC) * treatment naive or no treatment within 6 months prior to enrollment * able to swallow pills * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3 * absolute neutrophil count (ANC) at least 1500/microl * able to understand and willing to sign a written informed consent document Exclusion Criteria: * history of hypersensitivity reactions attributed to beta-glucan * currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy * presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements AIM 3: Inclusion Criteria: * resectable non-small cell lung cancer (NSCLC), as determined by a thoracic surgeon * treatment naive * able to swallow pills * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * must be an operative candidate * absolute neutrophil count (ANC) at least 1500/microl * able to understand and willing to sign a written informed consent document Exclusion Criteria: * history of hypersensitivity reactions attributed to beta-glucan * currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy * presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Study sites (1)
KY
- James Graham Brown Cancer Center · Louisville, KY 40202Goetz H Kloecker, MD · Principal investigatorMore trials in Louisville